Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.10)
# 533
Out of 4,981 analysts
107
Total ratings
52.17%
Success rate
13.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $52 → $66 | $56.84 | +16.12% | 5 | Aug 19, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $5.93 | +68.63% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $7.00 | +857.14% | 7 | Aug 14, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $12 → $6 | $1.02 | +488.24% | 1 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $3.07 | +356.03% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $30.31 | +322.30% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $394.53 | +4.17% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $6.97 | +172.60% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $465.89 | -10.92% | 9 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $11 → $10 | $3.16 | +216.46% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $105 | $96.22 | +9.12% | 8 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $11.42 | +372.85% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $17.32 | +281.06% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.20 | +400.00% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $17.39 | +762.56% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $54.09 | +55.30% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $114.55 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $6.45 | +3,620.93% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Aug 19, 2025
Maintains: Buy
Price Target: $52 → $66
Current: $56.84
Upside: +16.12%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.93
Upside: +68.63%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $7.00
Upside: +857.14%
Fractyl Health
Aug 14, 2025
Maintains: Buy
Price Target: $12 → $6
Current: $1.02
Upside: +488.24%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.07
Upside: +356.03%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $30.31
Upside: +322.30%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $394.53
Upside: +4.17%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $6.97
Upside: +172.60%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $465.89
Upside: -10.92%
Rocket Pharmaceuticals
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.16
Upside: +216.46%
Jul 18, 2025
Maintains: Buy
Price Target: $92 → $105
Current: $96.22
Upside: +9.12%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $11.42
Upside: +372.85%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $17.32
Upside: +281.06%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.20
Upside: +400.00%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $17.39
Upside: +762.56%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $54.09
Upside: +55.30%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $114.55
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $6.45
Upside: +3,620.93%